{"id":53529,"date":"2026-01-10T21:55:05","date_gmt":"2026-01-10T13:55:05","guid":{"rendered":"https:\/\/flcube.com\/?p=53529"},"modified":"2026-01-10T21:55:07","modified_gmt":"2026-01-10T13:55:07","slug":"indupro-partners-with-lilly-on-950m-oncology-deal-using-proximity-guided-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53529","title":{"rendered":"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform"},"content":{"rendered":"\n<p><strong>InduPro<\/strong> announced a <strong>global strategic collaboration, licensing agreement, and equity investment<\/strong> with <strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> to discover <strong>novel oncology treatments<\/strong> using InduPro&#8217;s <strong>proximity-guided platform<\/strong>. The multi-target deal, valued at up to <strong>USD\u202f950\u202fmillion<\/strong>, includes Lilly&#8217;s equity investment and access to InduPro&#8217;s <strong>AI\/ML-enabled membrane interactomics (MInt) platform<\/strong> for bispecific and multispecific antibody development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>InduPro, Eli Lilly (NYSE: LLY)<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Global strategic collaboration + licensing + equity investment<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>InduPro&#8217;s proximity-guided platform &amp; AI\/ML MInt platform<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Novel oncology treatments<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>Up to <strong>3 targets<\/strong><\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to <strong>USD\u202f950\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Lilly&#8217;s Role<\/strong><\/td><td>Equity investment; access to platform; early discovery collaboration<\/td><\/tr><tr><td><strong>InduPro&#8217;s Role<\/strong><\/td><td>Lead early discovery; identify co-target pairs; advance bispecific\/multispecific programs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-proximity-guided-platform\">Technology Profile: Proximity-Guided Platform<\/h2>\n\n\n\n<p><strong>Platform Mechanism<\/strong>: InduPro&#8217;s proprietary technology identifies <strong>co-target pairs<\/strong> on cell membranes that are in <strong>spatial proximity<\/strong>, enabling design of <strong>bispecific\/multispecific antibodies<\/strong> that <strong>simultaneously engage both targets<\/strong> with optimal geometry.<\/p>\n\n\n\n<p><strong>MInt Platform<\/strong>: <strong>AI\/ML-enabled membrane interactomics<\/strong> analyzes <strong>protein-protein interaction networks<\/strong> to predict <strong>functional co-targeting opportunities<\/strong> in oncology.<\/p>\n\n\n\n<p><strong>Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced specificity<\/strong>: Targets only cells where both antigens are co-localized<\/li>\n\n\n\n<li><strong>Improved potency<\/strong>: Proximity-driven avidity effects amplify therapeutic impact<\/li>\n\n\n\n<li><strong>Reduced toxicity<\/strong>: Spares normal tissues lacking target co-expression<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-equity-investment\">Financial Terms &amp; Equity Investment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Equity Investment<\/strong><\/td><td>Undisclosed<\/td><td>Lilly acquires minority stake in InduPro<\/td><\/tr><tr><td><strong>Collaboration Funding<\/strong><\/td><td>Embedded in $950M<\/td><td>Supports discovery efforts across 3 targets<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to $950M total<\/td><td>Tied to target validation, IND, clinical, regulatory, and commercial milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered<\/td><td>Mid\u2011single to low\u2011double digit on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Risk Sharing<\/strong>: Lilly\u2019s equity investment <strong>validates platform<\/strong> while allowing InduPro to retain <strong>operational control<\/strong> of early discovery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For InduPro<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011dilutive Funding<\/strong>: $950M potential provides <strong>5\u20117 years of runway<\/strong> without additional equity raises<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Lilly partnership <strong>credibility<\/strong> attracts future pharma partners<\/li>\n\n\n\n<li><strong>Pipeline Acceleration<\/strong>: Resources to advance <strong>6\u20118 internal programs<\/strong> beyond Lilly collaboration<\/li>\n<\/ul>\n\n\n\n<p><strong>For Lilly<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Gap Fill<\/strong>: Addresses <strong>oncology pipeline shortage<\/strong> after <strong>Retevmo<\/strong> and <strong>Verzenio<\/strong> patent cliffs<\/li>\n\n\n\n<li><strong>Next\u2011Gen Technology<\/strong>: Proximity\u2011guided platform offers <strong>first\u2011mover advantage<\/strong> in <strong>spatial biology\u2011driven drug design<\/strong><\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Early\u2011stage collaboration reduces <strong>per\u2011asset cost<\/strong> vs. <strong>$1\u20112\u202fbillion<\/strong> internal discovery spend<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-spatial-biology-in-oncology\">Market Opportunity: Spatial Biology in Oncology<\/h2>\n\n\n\n<p><strong>Global Oncology Drug Market<\/strong>: <strong>$200\u202fbillion<\/strong> (2025), with <strong>bispecific\/multispecific antibodies<\/strong> growing at <strong>25% CAGR<\/strong> to <strong>$50\u202fbillion<\/strong> by 2030.<\/p>\n\n\n\n<p><strong>Spatial Biology Market<\/strong>: <strong>$3.5\u202fbillion<\/strong> (2025), projected <strong>$12\u202fbillion<\/strong> by 2030, driven by <strong>need for precise target selection<\/strong>.<\/p>\n\n\n\n<p><strong>InduPro\u2019s Addressable Market<\/strong>: Each validated co\u2011target pair could unlock <strong>$2\u20115\u202fbillion<\/strong> in therapeutic value across <strong>CAR\u2011T, bispecifics, and ADCs<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway\">Development Pathway<\/h2>\n\n\n\n<p><strong>Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Selection<\/strong>: <strong>Q2\u202f2026<\/strong> (AI\u2011driven MInt analysis)<\/li>\n\n\n\n<li><strong>Lead Optimization<\/strong>: <strong>Q4\u202f2026<\/strong> (proximity\u2011guided antibody design)<\/li>\n\n\n\n<li><strong>IND Candidate<\/strong>: <strong>Q3\u202f2027<\/strong> (Lilly\u2011led preclinical development)<\/li>\n\n\n\n<li><strong>Clinical Trials<\/strong>: <strong>H1\u202f2028<\/strong> (Lilly assumes full development)<\/li>\n\n\n\n<li><strong>Commercial Launch<\/strong>: <strong>2032\u20112033<\/strong> (if successful)<\/li>\n<\/ul>\n\n\n\n<p><strong>Efficacy Bar<\/strong>: Must demonstrate <strong>superior tumor selectivity<\/strong> vs. monospecific antibodies to justify <strong>premium pricing<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding InduPro\u2019s discovery timeline, milestone achievements, and competitive positioning in spatial biology. Actual results may differ materially due to clinical validation challenges, competitive dynamics, and regulatory acceptance of novel platforms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,199,4501,911],"class_list":["post-53529","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-eli-lilly","tag-indupro-therapeutics","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE: LLY) to discover novel oncology treatments using InduPro&#039;s proximity-guided platform. The multi-target deal, valued at up to USD\u202f950\u202fmillion, includes Lilly&#039;s equity investment and access to InduPro&#039;s AI\/ML-enabled membrane interactomics (MInt) platform for bispecific and multispecific antibody development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53529\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform\" \/>\n<meta property=\"og:description\" content=\"InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE: LLY) to discover novel oncology treatments using InduPro&#039;s proximity-guided platform. The multi-target deal, valued at up to USD\u202f950\u202fmillion, includes Lilly&#039;s equity investment and access to InduPro&#039;s AI\/ML-enabled membrane interactomics (MInt) platform for bispecific and multispecific antibody development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53529\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-10T13:55:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-10T13:55:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53529#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53529\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform\",\"datePublished\":\"2026-01-10T13:55:05+00:00\",\"dateModified\":\"2026-01-10T13:55:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53529\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Eli Lilly\",\"InduPro Therapeutics\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53529#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53529\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53529\",\"name\":\"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-10T13:55:05+00:00\",\"dateModified\":\"2026-01-10T13:55:07+00:00\",\"description\":\"InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE: LLY) to discover novel oncology treatments using InduPro's proximity-guided platform. The multi-target deal, valued at up to USD\u202f950\u202fmillion, includes Lilly's equity investment and access to InduPro's AI\\\/ML-enabled membrane interactomics (MInt) platform for bispecific and multispecific antibody development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53529#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53529\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53529#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform - Insight, China&#039;s Pharmaceutical Industry","description":"InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE: LLY) to discover novel oncology treatments using InduPro's proximity-guided platform. The multi-target deal, valued at up to USD\u202f950\u202fmillion, includes Lilly's equity investment and access to InduPro's AI\/ML-enabled membrane interactomics (MInt) platform for bispecific and multispecific antibody development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53529","og_locale":"en_US","og_type":"article","og_title":"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform","og_description":"InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE: LLY) to discover novel oncology treatments using InduPro's proximity-guided platform. The multi-target deal, valued at up to USD\u202f950\u202fmillion, includes Lilly's equity investment and access to InduPro's AI\/ML-enabled membrane interactomics (MInt) platform for bispecific and multispecific antibody development.","og_url":"https:\/\/flcube.com\/?p=53529","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-10T13:55:05+00:00","article_modified_time":"2026-01-10T13:55:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53529#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53529"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform","datePublished":"2026-01-10T13:55:05+00:00","dateModified":"2026-01-10T13:55:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53529"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Eli Lilly","InduPro Therapeutics","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53529#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53529","url":"https:\/\/flcube.com\/?p=53529","name":"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-10T13:55:05+00:00","dateModified":"2026-01-10T13:55:07+00:00","description":"InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE: LLY) to discover novel oncology treatments using InduPro's proximity-guided platform. The multi-target deal, valued at up to USD\u202f950\u202fmillion, includes Lilly's equity investment and access to InduPro's AI\/ML-enabled membrane interactomics (MInt) platform for bispecific and multispecific antibody development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53529#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53529"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53529#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53529"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53529\/revisions"}],"predecessor-version":[{"id":53530,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53529\/revisions\/53530"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}